ProfileGDS4814 / ILMN_1763091
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 86% 85% 84% 87% 84% 83% 84% 84% 86% 83% 85% 87% 87% 84% 86% 85% 84% 86% 86% 84% 83% 85% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)267.53586
GSM780708Untreated after 4 days (C2_1)219.60985
GSM780709Untreated after 4 days (C3_1)215.56284
GSM780719Untreated after 4 days (C1_2)281.44587
GSM780720Untreated after 4 days (C2_2)212.58184
GSM780721Untreated after 4 days (C3_2)188.65483
GSM780710Trastuzumab treated after 4 days (T1_1)204.33684
GSM780711Trastuzumab treated after 4 days (T2_1)208.41884
GSM780712Trastuzumab treated after 4 days (T3_1)264.70986
GSM780722Trastuzumab treated after 4 days (T1_2)188.07883
GSM780723Trastuzumab treated after 4 days (T2_2)233.51585
GSM780724Trastuzumab treated after 4 days (T3_2)302.54687
GSM780713Pertuzumab treated after 4 days (P1_1)277.10887
GSM780714Pertuzumab treated after 4 days (P2_1)207.95684
GSM780715Pertuzumab treated after 4 days (P3_1)258.95586
GSM780725Pertuzumab treated after 4 days (P1_2)224.21285
GSM780726Pertuzumab treated after 4 days (P2_2)215.17684
GSM780727Pertuzumab treated after 4 days (P3_2)261.25286
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)251.76386
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)218.82484
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)196.56183
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)235.88185
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)214.92984